These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy. Yu YH; Shere Y; Vigneswaran N Tex Dent J; 2012 Aug; 129(8):764-5, 786-8. PubMed ID: 22988661 [No Abstract] [Full Text] [Related]
8. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Khoo TL; Catalano A; Supple S; Chong L; Yeoh SC; Yeung S; Iland H Leuk Lymphoma; 2013 Jan; 54(1):186-8. PubMed ID: 22712835 [No Abstract] [Full Text] [Related]
9. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature. Wong M; Sade S; Gilbert M; Klieb HB Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826 [TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Druker BJ Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592 [TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. Hernández-Boluda JC; Cervantes F Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448 [TBL] [Abstract][Full Text] [Related]
13. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Ikuta K; Torimoto Y; Jimbo J; Inamura J; Shindo M; Sato K; Tokusashi Y; Miyokawa N; Kohgo Y Int J Hematol; 2005 Nov; 82(4):343-6. PubMed ID: 16298828 [TBL] [Abstract][Full Text] [Related]
15. Skin and oral lesions associated to imatinib mesylate therapy. Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666 [TBL] [Abstract][Full Text] [Related]
16. Targeted chronic myeloid leukemia therapy: Seeking a cure. Fausel C Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932 [TBL] [Abstract][Full Text] [Related]
18. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Govind Babu K; Attili VS; Bapsy PP; Anupama G Int Ophthalmol; 2007 Feb; 27(1):43-4. PubMed ID: 17410337 [TBL] [Abstract][Full Text] [Related]
19. Imatinib-associated hyperpigmentation, a side effect that should be recognized. Mcpherson T; Sherman V; Turner R J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557 [No Abstract] [Full Text] [Related]
20. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. Aleem A Hematol Oncol Stem Cell Ther; 2009; 2(2):358-61. PubMed ID: 20118061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]